This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Travagli, J. P. Articles by Schlumberger, M. Search for Related Content PubMed PubMed Citation Articles by Travagli, J. P. Articles by Schlumberger, M.

Combination of Radioiodine (¹³¹I) and Probe-Guided Surgery for Persistent or Recurrent Thyroid Carcinoma

Institut Gustave-Roussy, 94 805 Villejuif Cedex, France

Address all correspondence and requests for reprints to: M. Schlumberger, M.D., Service de Médecine Nucléaire, Institut Gustave-Roussy, 39 rue C. Desmoulins, 94805 Villejuif Cedex, France.

To improve the completeness of surgical excision of persistent or recurrent differentiated thyroid carcinoma, the following protocol was used for the treatment of 54 patients with functioning lymph node metastases: administration of 3.7 gigabecquerels (100 mCi) ¹³¹I; total body scintigraphy (TBS) on day 4; surgery on day 5, using an intraoperative probe (Gammed 2, Eurorad); and postoperative TBS with the remaining ¹³¹I activity on day 7.

The 54 patients (35 women and 19 men presenting 47 papillary carcinomas, 2 well differentiated follicular carcinomas, and 5 poorly differentiated follicular carcinomas) had already undergone surgery for differentiated thyroid carcinoma: total thyroidectomy (51 patients) or lobectomy with isthmusectomy (3 patients), with lymph node dissection in 33. One to 7 ¹³¹I treatments were performed before inclusion.

Preoperative ¹³¹I-TBS with a high dose of ¹³¹I allowed accurate localization of previously suspected neoplastic foci and detection of yet unknown foci in 56%; it was the most sensitive tool for localizing neoplastic foci. The use of an intraoperative probe was considered decisive in 20 patients, as neoplastic foci were found inside sclerosis due to previous surgery (n = 9), at unusual sites behind vessels or in the mediastinum (n = 10), or both (n = 1). In 26 patients, it facilitated the preoperative detection of foci with ¹³¹I uptake already depicted at preoperative ¹³¹I-TBS. In all 46 patients, the completeness of excision was demonstrated by both the probe and the postoperative ¹³¹I-TBS and was confirmed during follow-up. Of note, lymph node metastases undetected by ¹³¹I-TBS or by the probe were found in 14 patients at histological examination. This clearly shows that en block dissection is the only recommended procedure.

In four patients, no neoplastic foci were found and in four patients, uptake was either due to the thymus (in two) or to the salivary glands (in two).

This article has been cited by other articles:

				S. Leboulleux, P. R. Schroeder, N. L. Busaidy, A. Auperin, C. Corone, H. A. Jacene, M. E. Ewertz, C. Bournaud, R. L. Wahl, S. I. Sherman, et al. Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1310 - 1316. [Abstract] [Full Text] [PDF]

				T. Pilli, E. Brianzoni, F. Capoccetti, M. G. Castagna, S. Fattori, A. Poggiu, G. Rossi, F. Ferretti, E. Guarino, L. Burroni, et al. A Comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-Iodine Administered Doses for Recombinant Thyrotropin-Stimulated Postoperative Thyroid Remnant Ablation in Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3542 - 3546. [Abstract] [Full Text] [PDF]

				M. Schlumberger, A. Hitzel, M. E. Toubert, C. Corone, F. Troalen, M. H. Schlageter, F. Claustrat, S. Koscielny, D. Taieb, M. Toubeau, et al. Comparison of Seven Serum Thyroglobulin Assays in the Follow-Up of Papillary and Follicular Thyroid Cancer Patients J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2487 - 2495. [Abstract] [Full Text] [PDF]

				F. Triponez, L. Poder, R. Zarnegar, R. Goldstein, K. Roayaie, V. Feldstein, J. Lee, E. Kebebew, Q.-Y. Duh, and O. H. Clark Hook Needle-Guided Excision of Recurrent Differentiated Thyroid Cancer in Previously Operated Neck Compartments: A Safe Technique for Small, Nonpalpable Recurrent Disease J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4943 - 4947. [Abstract] [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]

				F. Pacini, L. Agate, R. Elisei, M. Capezzone, C. Ceccarelli, F. Lippi, E. Molinaro, and A. Pinchera Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4092 - 4097. [Abstract] [Full Text] [PDF]

				A. F. Cailleux, E. Baudin, J. P. Travagli, M. Ricard, and M. Schlumberger Is Diagnostic Iodine-131 Scanning Useful after Total Thyroid Ablation for Differentiated Thyroid Cancer? J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 175 - 178. [Abstract] [Full Text]